Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress
EM De Francesco, F Cirillo, V Vella… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Triple-negative breast cancer (TNBC) is a heterogeneous disease
characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and …
characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and …
[PDF][PDF] Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer
Quantitative systems pharmacology (QSP) modeling is an emerging mechanistic
computational approach that couples drug pharmacokinetics/pharmacodynamics and the …
computational approach that couples drug pharmacokinetics/pharmacodynamics and the …
[HTML][HTML] Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses
S Li, N Zhang, H Zhang, R Zhou, Z Li, X Yang, W Wu… - Journal of Big Data, 2023 - Springer
Triple-negative breast cancer (TNBC) is a relatively aggressive breast cancer subtype due to
tumor relapse, drug resistance, and multi-organ metastatic properties. Identifying reliable …
tumor relapse, drug resistance, and multi-organ metastatic properties. Identifying reliable …
Triple negative breast cancer: from biology to clinical practice
N Hajjaji, O Trédan - Innovations & Thérapeutiques en Oncologie, 2022 - jle.com
Les cancers du sein triples négatifs (CSTN) sont un groupe très hétérogène de différentes
entités biologiques et pathologiques. Ils peuvent donc être découpés en fonction de profils …
entités biologiques et pathologiques. Ils peuvent donc être découpés en fonction de profils …